Co-amilofruse (BAN) is a nonproprietary name used to denote a combination of amiloride and furosemide, which are both diuretics.[1] Co-amilofruse is a treatment for fluid retention (oedema), either in the legs (peripheral edema) or on the lungs (pulmonary oedema). Furosemide is a loop diuretic and is more effective than amiloride, but has a tendency to cause low potassium levels (hypokalaemia); the potassium-sparing effects of amiloride may balance this.
| Combination of | |
|---|---|
| Amiloride | Potassium-sparing diuretic |
| Furosemide | Loop diuretic |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?) (verify) | |
Formulation
editTwo strengths of co-amilofruse are available:
- 2.5 mg amiloride with 20 mg furosemide, BAN of Co-amilofruse 2.5/20 (brand name Frumil LS)
- 5 mg amiloride with 40 mg furosemide, BAN of Co-amilofruse 5/4-0 (brand name Frumil)
References
edit- ^ Hitchings A, Lonsdale D, Burrage D, Baker E (2014). Top 100 drugs : clinical pharmacology and practical prescribing. Edinburgh: Elsevier Health Sciences. p. 113. ISBN 978-0-7020-5515-7.
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |